Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

2.8 / 5 stars · 68/120 Roast Me

EDITAS MEDICINE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

EDITAS MEDICINE, INC. (EDIT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 439.87 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-05

  • EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 364.29K shares.
  • EDITAS MEDICINE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 75.58K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month
2026-06-30364.29K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
439.87K shares
10-Q · filed 2026-08-05
2026-03-3175.58K shares
10-Q · filed 2026-05-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30